Drug Trial Radar · NCT00269893
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
Last checked: Nov 20, 2026Latest source record: Jun 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,038
Actual
Start
Nov 1991
Primary completion
Nov 1992
Study completion Nov 1992
Sponsor
- Lead sponsor
- Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of abciximab (an anti-platelet therapy) versus placebo in patients undergoing high risk coronary angioplasty.
Conditions
- Angina, Unstable
- Angioplasty, Transluminal, Percutaneous Coronary
Interventions
AbciximabDrug
0.25 mg/kg of body weight of abciximab either bolus or infusion.
PlaceboDrug
Matching Placebo soulution either bolus or infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Any of the following within 30 days: Death from any cause; Myocardial infarction; Recurrent ischemic event requiring urgent intervention (repeat angioplasty, coronary artery bypass surgery, intracoronary stent placement, or intra-aortic balloon pump).Time frame: 30 days after angioplasty
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.